Firms competitive strategy

In the multi-criteria model, the overall demand fulfillment ratio increased to 99% with some reduction in profits. A valuable outcome of this analysis was the trade-off evaluations for specific product-market combinations, where increases in sales reduced profitability. These insights led to valuable managerial implications for the evaluation of the firms competitive strategy. 

Most firms have a competitive strategy an idea of how they do things and what they want to be. Figure 18-5 shows four typical strategies. You might think that a firm should aim at all good things simultaneously, but experience shows that that does not work. A firm has to make choices. 

Generally, available information on material flows provided by MFCA along upstream and downstream firms in a supply chain can ensure for reducing material losses and help to supply chain managers that have an effective decision on resource productivity as well as improvement in competitive strategies such as product variety and quality, while cost reduction is happened. 

Phase I starts with a clear definition of the firm s competitive strategy as the set of customer needs that the supply chain aims to satisfy. The supply chain strategy then specifies what capabilities the supply chain netwoik must have to support the competitive strategy (see Chapter 2). Next, managers must forecast the likely evolution of global competition and whether competitors... 

Based on the competitive strategy of the firm, its resulting supply chain strategy, an analysis of the competition, any economies of scale or scope, and any constraints, managers must determine the broad supply chain design for the firm. 

Thus, brands allow product differentiation, which, according to market theory and empirical evidence, results in a higher price than would be the case with perfect competition. Yet whereas patents provide rewards and incentives for those companies that assume the economic effort and the risk involved in research, brands benefit any company that has the wherewithal to develop effective marketing strategies and give doctors incentives to prescribe its products, regardless of their therapeutic value and the possible research orientation of the firm. 

On the supply side, patents allow the innovating company considerable discretion in pricing their new products. However, new products may be complements or substitutes of those of rival companies. In reality, pharmaceutical firms operate in oligopolistic markets characterized by a limited number of competitors (especially in submarkets such as that of cardiovascular products, for example), differentiated products and competitive innovation strategies. 

Arguably, the most effective life cycle management strategy is the introduction of a new class of therapies. Competition evolves in pharmaceuticals by the introduction of new classes of entities with superior therapeutic properties to prior generations of products. Firms that have a commercially... 

However, they also represent a competitive threat that needs close observation. By examining buyout firms, chemical executives can gain deep insights for their own strategies and the set of value generation mechanisms that they themselves should apply. 

---